A Comparative Effectiveness Study of Positive Airway Pressure (PAP) Therapy, Dental Device, and Atomoxetine-Oxybutynin for Treatment of Obstructive Sleep Apnea in Adults

Researchers want to identify which treatments for obstructive sleep apnea (OSA) work best and are easiest for patients to use consistently. Eligible participants will be randomly assigned one of three OSA treatments: traditional PAP therapy, a dental device, or a combination of two FDA-approved medications (atomoxetine and oxybutynin) that are currently approved for other conditions. Over the course of one year, participants will attend two in-person visits and take part in four phone check-ins to complete surveys, report any side effects, and discuss how well they are following their assigned treatment.

NCT Number	NCT07679282
Lead Sponsor	Sairam Parthasarathy Collaborators: Patient-Centered Outcomes Research Institute, University of Arizona, University of Maryland, University of Miami, Stanford University
Conditions	Obstructive Sleep Apnea (OSA)
Enrollment	2,400 participants
Start Date	2026-09-01
Primary Completion	2030-03-01 (estimated)
Study Completion	2032-05-01 (estimated)
Updated on ClinicalTrials.gov	2026-08-13